pharmaphorum January 18, 2021
Phil Taylor

Developers of digital health tools have benefited from a truncated route to market during the COVID-19 crisis, and that could be made permanent if new FDA guidance is adopted.

Pandemic emergency provisions were put in place in March last year to allow certain medical devices to be launched for use by patients without having to go through the FDA’s usual premarket notification requirements – also known as the 510(k) process.

That included some low-risk (Class IIa) digital health apps under the software as a medical device (SaMD) category, which can be used to minimise direct contact between patients and healthcare professionals at a time when non-essential visits are best avoided.

Now, the FDA is seeking comment on plans to make...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Regulations, Technology
March Fundraising Roundup: 7 Provider Tech Startups That Closed Rounds This Month
Pelago Defies Digital Health Funding Drought, Raises $58M
Digital health venture capital deals stagnate
Finger on the Pulse: The State of Primary Care in the U.S. and Nine Other Countries
Embracing digital transformation with a digital factory

Share This Article